Racura Oncology Ltd (ASX:RAC)

Racura Oncology Statistics

Total Valuation

Racura Oncology has a market cap or net worth of AUD 505.17 million. The enterprise value is 491.50 million.

Market Cap	505.17M
Enterprise Value	491.50M

Important Dates

The next estimated earnings date is Tuesday, February 24, 2026.

Earnings Date	Feb 24, 2026
Ex-Dividend Date	n/a

Share Statistics

Racura Oncology has 179.14 million shares outstanding. The number of shares has increased by 4.81% in one year.

Current Share Class	179.14M
Shares Outstanding	179.14M
Shares Change (YoY)	+4.81%
Shares Change (QoQ)	-11.12%
Owned by Insiders (%)	27.43%
Owned by Institutions (%)	2.65%
Float	126.11M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	83.60
PB Ratio	31.55
P/TBV Ratio	37.47
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Enterprise Valuation

EV / Earnings	-102.67
EV / Sales	81.33
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 10.29

Current Ratio	10.29
Quick Ratio	9.42
Debt / Equity	n/a
Debt / EBITDA	n/a
Debt / FCF	n/a
Interest Coverage	n/a

Financial Efficiency

Return on equity (ROE) is -27.89% and return on invested capital (ROIC) is -17.17%.

Return on Equity (ROE)	-27.89%
Return on Assets (ROA)	-15.63%
Return on Invested Capital (ROIC)	-17.17%
Return on Capital Employed (ROCE)	-29.40%
Revenue Per Employee	n/a
Profits Per Employee	n/a
Employee Count	n/a
Asset Turnover	0.32
Inventory Turnover	n/a

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +110.45% in the last 52 weeks. The beta is 1.10, so Racura Oncology's price volatility has been higher than the market average.

Beta (5Y)	1.10
52-Week Price Change	+110.45%
50-Day Moving Average	3.13
200-Day Moving Average	1.95
Relative Strength Index (RSI)	49.26
Average Volume (20 Days)	164,977

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, Racura Oncology had revenue of AUD 6.04 million and -4.79 million in losses. Loss per share was -0.03.

Revenue	6.04M
Gross Profit	5.41M
Operating Income	-4.72M
Pretax Income	-4.79M
Net Income	-4.79M
EBITDA	-4.43M
EBIT	-4.72M
Loss Per Share	-0.03

Balance Sheet

The company has 13.67 million in cash and n/a in debt, giving a net cash position of 13.67 million or 0.08 per share.

Cash & Cash Equivalents	13.67M
Total Debt	n/a
Net Cash	13.67M
Net Cash Per Share	0.08
Equity (Book Value)	16.01M
Book Value Per Share	0.09
Working Capital	13.51M

Cash Flow

Operating Cash Flow	-4.57M
Capital Expenditures	n/a
Free Cash Flow	n/a
FCF Per Share	n/a

Margins

Gross margin is 89.49%, with operating and profit margins of -78.03% and -79.22%.

Gross Margin	89.49%
Operating Margin	-78.03%
Pretax Margin	-79.22%
Profit Margin	-79.22%
EBITDA Margin	-73.37%
EBIT Margin	-78.03%
FCF Margin	n/a

Dividends & Yields

Racura Oncology does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-4.81%
Shareholder Yield	-4.81%
Earnings Yield	-0.95%
FCF Yield	n/a

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Racura Oncology has an Altman Z-Score of 92.35 and a Piotroski F-Score of 3.

Altman Z-Score	92.35
Piotroski F-Score	3